Angela Alexander
Overview
Explore the profile of Angela Alexander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Zhao L, Song X, Wu X, Krishnamurthy S, Semba T, et al.
NPJ Precis Oncol
. 2024 Nov;
8(1):265.
PMID: 39558017
Triple-negative inflammatory breast cancer (TN-IBC) is the most aggressive type of breast cancer, yet its defining genomic, molecular, and immunological features remain largely unknown. In this study, we performed the...
2.
Hao X, Shen Y, Liu J, Alexander A, Wu L, Xu Z, et al.
Nat Cell Biol
. 2024 Sep;
26(11):1971-1983.
PMID: 39266726
Solid tumours induce systemic immunosuppression that involves myeloid and T cells. B cell-related mechanisms remain relatively understudied. Here we discover two distinct patterns of tumour-induced B cell abnormality (TiBA; TiBA-1...
3.
Iwase T, Cohen E, Gao H, Alexander A, Kai M, Chiv V, et al.
Clin Cancer Res
. 2024 Apr;
30(11):2424-2432.
PMID: 38629963
Purpose: Accumulating toxicities hinder indefinite chemotherapy for many patients with metastatic/recurrent HER2-negative breast cancer. We conducted a phase II trial of pembrolizumab monotherapy following induction chemotherapy to determine the efficacy...
4.
Hao X, Shen Y, Chen N, Zhang W, Valverde E, Wu L, et al.
Cell Stem Cell
. 2023 May;
30(5):648-664.e8.
PMID: 37146584
Remote tumors disrupt the bone marrow (BM) ecosystem (BME), eliciting the overproduction of BM-derived immunosuppressive cells. However, the underlying mechanisms remain poorly understood. Herein, we characterized breast and lung cancer-induced...
5.
Whisenant M, Alexander A, Woodward W, Teshome M, Ueno N, Williams L
Cancer Nurs
. 2023 Feb;
47(1):E65-E72.
PMID: 36729801
Background: Inflammatory breast cancer (IBC) is an aggressive, locally advanced cancer with a 5-year survival rate of approximately 40%. Although patients with IBC likely experience significant and variable symptom burden...
6.
7.
Nilanon T, Nocera L, Martin A, Kolatkar A, May M, Hasnain Z, et al.
JCO Clin Cancer Inform
. 2020 Sep;
4:839-853.
PMID: 32970482
Purpose: Unplanned health care encounters (UHEs) such as emergency room visits can occur commonly during cancer chemotherapy treatments. Patients at an increased risk of UHEs are typically identified by clinicians...
8.
Langran C, Alexander A, Donyai P
Am J Pharm Educ
. 2020 Apr;
84(3):7026.
PMID: 32313273
To implement and evaluate the effectiveness of healthy living assessments (HLA) conducted on campus by undergraduate pharmacy students. Because of a shortage of workplace-based placements for undergraduate pharmacy students, a...
9.
Chen X, Low K, Alexander A, Jiang Y, Karakas C, Hess K, et al.
Clin Cancer Res
. 2018 Sep;
24(24):6594-6610.
PMID: 30181387
Purpose: Poor prognosis in triple-negative breast cancer (TNBC) is due to an aggressive phenotype and lack of biomarker-driven targeted therapies. Overexpression of cyclin E and phosphorylated-CDK2 are correlated with poor...
10.
Ueno N, Fernandez J, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, et al.
J Cancer
. 2018 May;
9(8):1437-1447.
PMID: 29721054
National and international experts in inflammatory breast cancer (IBC) from high-volume centers treating IBC recently convened at the 10th Anniversary Conference of the Morgan Welch Inflammatory Breast Cancer Research Program...